- 询价
- MedChemExpress(MCE)
- 美国
- HY-130707
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
-20°C, stored under nitrogen
- 库存：
货期：询盘
- 供应商：
MedChemExpress LLC
- CAS号：
2378261-87-9
- 规格：
询盘
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
K-Ras ligand-Linker Conjugate 3
CAS No. : 2378261-87-9
MCE 国际站：K-Ras ligand-Linker Conjugate 3
产品活性：K-Ras ligand-Linker Conjugate 3 (Compound 001371) 包含靶蛋白 K-Ras 配体 (K-Ras 募集基序) 和 PROTAC linker，可募集 E3 连接酶 (如 VHL，CRBN，MDM2 和 IAP 等类型)。K-Ras ligand-Linker Conjugate 3 可用于合成 PROTAC K-Ras Degrader-1 (HY-129523)，PROTAC K-Ras Degrader-1 是一种有效的 PROTAC K-Ras 降解剂，在 SW1573 中对 K-Ras 的降解率 ≥70%。
研究领域：PROTAC
作用靶点：Target Protein Ligand-Linker Conjugates
In Vitro: PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
相关产品：BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride | Desmorpholinyl Quizartinib-PEG2-COOH | FAK ligand-Linker Conjugate 1 | K-Ras ligand-Linker Conjugate 6 | (Rac)-PROTAC PARP/EGFR ligand 1 | Ahx-DM1 | BRD4 ligand-Linker Conjugate 1 | EN884 | ERRα Ligand-Linker Conjugates 1 | K-Ras ligand-Linker Conjugate 1 | K-Ras ligand-Linker Conjugate 2 | K-Ras ligand-Linker Conjugate 4 | K-Ras ligand-Linker Conjugate 5 | MRTX849 ethoxypropanoic acid | PROTAC SMARCA2 degrader-1
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验AntibodyDrug Conjugate (ADC) Clinical Pipeline: A Review
game, requiring thoughtful combination of antibody, linker, and drugs in the context of a target and a defined cancer indication. Lessons learned from the first-generation antibody–drug conjugate (ADC) and improvement of the technology guided the design
In Vivo Testing of Drug-Linker Stability
drug release in circulation and efficiently converted into active drugs in the tumor tissues. Designing the right combination of monoclonal antibody (mAb), linker and drug, requires monitoring and understanding the behavior of all three components
Attachment of Reporter and Conjugate Groups to the 3′ Termini of Oligonucleotides
Figure 4.5.1 Generic oligonucleotide 3′‐conjugate. View Image
技术资料暂无技术资料 索取技术资料
